Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145314
Status:
COMPLETED
Last Update Posted:
2011-01-14
First Post:
2005-09-02
Brief Title:
FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer
Sponsor:
The Nordic Colorectal Cancer Biomodulation Group
Organization:
The Nordic Colorectal Cancer Biomodulation Group
Study Overview
Official Title:
5-FluorouracilFolinateOxaliplatin Eloxatin FLOX Regimen Given Continuously or Intermittently in Combination With Cetuximab Erbitux in First-line Treatment of Metastatic Colorectal Cancer A Phase III Multicenter Trial
Status:
COMPLETED
Status Verified Date:
2011-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main objective of this trial is to explore the effect of combining an established chemotherapy regimen FLOX based on 5-fluorouracil folinic acid and oxaliplatin Eloxatin with the EGF receptor antibody cetuximab Erbitux in first-line treatment of metastatic colorectal cancer The trial will investigate two regimens of FLOX plus cetuximab in which FLOX is given continuously or intermittently compared to standard FLOX without cetuximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EudraCT no 2005-000117-34 | None | None | None |